Sarcoidosis related Calcium Dysregulation for Sarcoidosis

Phase 2 & 3

Waitlist Available

Led By Marc A Judson, MD

Research Sponsored by Albany Medical College

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up between week 0 and week 12.

Awards & highlights

Approved for 5 Other Conditions

No Placebo-Only Group

Summary

ACTHAR Gel has activity in sarcoidosis associated hypercalciuria and calcium dysregulation.

Eligible Conditions

Sarcoidosis

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ between week 0 and week 12.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~between week 0 and week 12.

This trial's timeline: 3 weeks for screening, Varies for treatment, and between week 0 and week 12. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Reduction of 24 hour urine calcium

Awards & Highlights

Approved for 5 Other Conditions

This treatment demonstrated efficacy for 5 other conditions.

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Sarcoidosis related Calcium DysregulationExperimental Treatment1 Intervention

Subjects with Sarcoidosis associated calcium dysregulation will be administered 80 units of Acthar Gel (adrenocorticotropic hormone) twice a week for 12 weeks. Clinical visits will be scheduled for -30 days, day of 1st dose and 4,8,12 and 16 week after 1st dose to monitor the health of subjects.

Do I qualify?Apply below to find out